Biofilm-Associated Infections

Antibiotic Resistance and Novel Therapeutic Strategies

Fengjun Sun; Feng Qu; Yan Ling; Panyong Mao; Peiyuan Xia; Huipeng Chen; Dongsheng Zhou


Future Microbiol. 2013;8(7):877-886. 

In This Article

Conclusion & Future Perspective

The infectious biofilms attached to living (tissues) and nonliving (indwelling medical devices) surfaces can trigger inflammation in the human body, which is a specific form of persistent infection. The biofilms have evolved significantly increased antibiotic resistance relative to their free-floating counterparts, severely hampering the successful treatment of biofilm-associated infections. The increased antimicrobial resistance results from the simultaneous operation of multiple biofilm-specific mechanisms that are still not fully understood. Deeper understanding of these mechanisms will be useful for the development of new antibiofilm agents, from which innovative therapeutic measures may be developed to eradicate persistent infections. Particularly, studies on biofilms from in vivo and clinical sources, by using genome sequencing, comparative genomics, proteomics and other multidimensional technologies, have opened the door to a new wave of dissecting mechanisms of biofilm-specific antimicrobial resistance and of designing and developing novel antibiofilm agents. In the near future, sophisticated drug cocktails, which are pathogen-specific and composed of classic small-molecule antibiotics as well as novel antibiofilm agents, may well be routinely applied to treat biofilm-associated infections.